Brief: Obseva Announces Ind Approval For Yuyuan Bioscience’S Phase 1 Clinical Trial Of Nolasiban In China
13/10/2022 12:09
Oct 13 (Reuters) - Obseva SA OBSN.S :
* OBSEVA ANNOUNCES IND APPROVAL FOR YUYUAN BIOSCIENCE’S
PHASE 1
CLINICAL TRIAL OF NOLASIBAN IN CHINA
Source text for Eikon: ID:nGNX669CyX
Further company coverage: OBSN.S
Recent news on Obseva SA
See all newsBrief: Obseva Announces Wind-Down Of Operations And Likely Not Going To Be Able To Satisfy Requirements For Maintaining Its Listing
Brief: Obseva Applies For Moratorium To Facilitate Pivotal Deals
Brief: Obseva SA Says Xoma Will Receive Full Worldwide Rights On Ebopiprant Following Termination Of License Agreement With Organon
Brief: Obseva Appoints Fabien De Ladonchamps As Chief Executive Officer Effective May 1, 2023
Brief: Obseva Announces Change Of Central Securities Depositary